Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Hopebridge and Akiva Partner for Virtual Reality Additive Design Clinical Pilots

Indianapolis, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Hopebridge Autism Therapy Centers, the largest autism therapy healthcare provider in the nation, is advancing autism spectrum disorder (ASD) research through groundbreaking new virtual reality additive design pilots. Hopebridge’s clinical pilots will implement VR within applied behavior analysis (ABA therapy) programs in several centers across the country.

Hopebridge’s pilots will utilize Akiva, an immersive virtual reality learning experience that combines gaming with artificial intelligence to create a predictable learning ecosystem that enables children with special needs to develop sensory, cognitive, perceptual and fine motor skills. Hopebridge’s employment of Akiva through Oculus Quest VR headsets will allow clinicians to monitor and record the additive benefits of VR paired with applied behavior analysis (ABA) therapy to enhance the rate of acquisition of behavior skills in children with autism.

Leading the study is Hopebridge Chief Science Officer, Dr. Adam Hahs. “Virtual reality holds tremendous potential to both enhance and improve the way we deliver care to our patients,” said Dr. Hahs. “Our partnership with Akiva demonstrates our commitment to innovation and the growing digital therapeutic market. Our clinicians are empowered to utilize customized technology, infrastructure and research solutions to accelerate critical early intervention for patient development.”

While the applicability of VR was never in question, the reach is soon to be realized given the recent announcement of a billing code for services affording families this opportunity. With payor recognition of VR, families will be able to access a treatment in ABA that is the gold standard in the health care vertical.

The clinical pilots with Akiva will focus on studying an in-center VR therapy program, with Akiva software collecting data and patient outcomes. The cloud-based software will provide real-time data tracking for clinical outcomes including:

  • Labeling objects, numbers, and letters
  • Speech production and articulation
  • Social skills
  • Vestibular and proprioceptive awareness
  • Eye tracking and joint attention
  • Speed of response (latency)

“At Akiva, our vision is to enable neurodivergent individuals to learn, self-explore, and thrive on developing their unique abilities,” said Akiva CEO Alexander Landa. “The proliferation of virtual reality and machine learning has expanded the ways in which companies like Hopebridge can provide care that is safe, immersive, and fun to the recipients, while data-driven, objective improvements are shared with all members of the ecosystem. Akiva is working closely with Hopebridge to refine and develop the platform functionality blueprint that will revolutionize early intervention.”   

Data tracking for phase one pilots will inform the execution and delivery of phase two, which consists of wide-scale, randomized controlled trial (RCT) to be launched across the entire Hopebridge footprint in 2023.

In March, the organization announced a new clinical division with executive appointments to support initiatives for enhancing clinical outcomes and an increasing value-based care model. Dr. Hahs was appointed Chief Science Officer for the organization, charged with driving the multi-state organization towards enhanced clinical outcomes, value-based healthcare, research initiatives and clinical innovation.

Dr. Hahs also leads Hopebridge’s participation in the International Consortium for Health Outcomes Measurement (ICHOM), as well as heading up exclusive continuing education opportunities for clinicians like PEAK training. Hahs has been fundamental in the development of one of the largest clinical supervision programs in the industry, the Hopebridge Fellowship Program, as well as driving strategies for large internal and external research initiatives in the behavioral health space.

­For more information on Hopebridge centers and services, visit hopebridge.com/centers.

###

 About Hopebridge

 Hopebridge was founded in 2005 to serve the growing need for autism treatment services and to improve the lives of affected children and families. Hopebridge is committed to providing personalized outpatient ABA, occupational, speech and feeding therapies for children touched by autism spectrum disorder and behavioral, physical, social, communication and sensory challenges. Hopebridge provides a trusted place where they can receive the care, support and hope they deserve.

 More than a decade later, Hopebridge continues to open state-of-the-art autism therapy centers in new communities to reach patients and families who need services. Headquartered in Indianapolis, Hopebridge operates over 100 centers in the following twelve states: Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Indiana, Kentucky, North Carolina, Oklahoma, Ohio and Tennessee.

Attachment


Samantha Sandala
Hirons
(608) 575-2784
ssandala@hirons.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.